Finally, the results highlighted that isoviolanthin could markedly inhibit TGF-β1-mediated migration and invasion by deactivating EMT via the TGF-β/Smad and PI3K/Akt/mTOR pathways, indicating that isoviolanthin may be a potential anticancer agent for the treatment of metastatic HCC. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.